NCT05481658招募中1 期
A Phase I, Open Label Study Employing the Topical Immunomodulator Diphencyprone to Improve Efficacy of PD-1 or PD-L1 Immune Checkpoint Inhibition in the Treatment of Advanced Cancer With Cutaneous Metastases
Nicholas Gulati1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2022年10月6日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Proportion of subjects with a grade 3 adverse event
研究概览
简要总结
This is a phase I, open label study employing diphencyprone (DPCP) to characterize gene expression changes of various immune cell and tumor markers in cutaneous metastases treated with topical DPCP twice weekly for 12 weeks in combination with PD-1 or PD-L1 immune checkpoint inhibition (ICI), compared to pre-treatment cutaneous metastases and to describe the adverse events associated with DPCP when administered topically twice weekly for 12 weeks in combination with PD-1 or PD-L1 ICI.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinically diagnosed cancer with at least three cutaneous metastasis sites that are able to be biopsied.
- •Subject's oncologist plans as next standard of care treatment to use an FDA- approved PD-1 or PD-L1 ICI therapy. In other words, the subject would be treated with PD-1 or PD-L1 ICI therapy even if not taking part in this study. Subjects can be either ICI-naïve (never having received ICI previously), or may have progressed/relapsed during ICI therapy, but the treating oncologist has elected to continue PD-1 or PD-L1 ICI therapy.
- •Age ≥ 18 years.
- •Eastern Cooperative Oncology Group (ECOG) performance status 0-
- •Women of child-bearing potential and men must agree to use adequate contraception prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately:
- •A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
- •Has not undergone a hysterectomy or bilateral oophorectomy; or
- •Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).
- •Ability to understand and the willingness to sign a written informed consent.
排除标准
- •Subjects may not be receiving any other investigational agents.
- •Subjects must not be receiving combination ICI, such as a PD-1 inhibitor with a CTLA-4 inhibitor.
- •Subjects taking any of the following systemic therapies: corticosteroids, immunosuppressants, and/or any other medications (systemic or topical) that may affect the outcome of the study in the opinion of the investigator
- •Subjects with any underlying diseases or dermatological conditions of the affected areas that require the use of interfering topical or systemic therapy, or that may, in the opinion of the investigator, impair immune responses such as HIV or lymphadenectomy of the axillary lymph node basin that drains the skin where DPCP is to be applied.
- •History of allergic reactions attributed to compounds of similar chemical or biologic composition to DPCP, or any of the other components of the DPCP ointment formulation.
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- •Subjects must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants.
研究组 & 干预措施
Diphencyprone (DPCP)
Experimental
0.4% and 0.04% ointment
干预措施: Diphencyprone (DPCP) (Drug)
结局指标
主要结局
Proportion of subjects with a grade 3 adverse event
时间窗: at Day 98 or 128
Safety and tolerability of dual-therapy DPCP plus immune checkpoint inhibition will be measured as the proportion of subjects with a grade 3 on the Common Terminology Criteria for Adverse Events (CTCAE) criteria for eczema, version 5.0.
次要结局
未报告次要终点
研究者
Nicholas Gulati
Assistant Professor
Icahn School of Medicine at Mount Sinai
研究点 (1)
Loading locations...
相似试验
尚未招募
1 期
A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive GlioblastomaSolid TumorGlioblastoma Multiforme of BrainGlioblastomaGlioblastoma MultiformeNCT05095441ImmVira Pharma Co. Ltd51
已完成
1 期
CP-751,871 In Combination With Docetaxel In Advance Non-hematologic MalignanciesAdvanced Non-Hematologic MalignanciesNCT01653158Pfizer46
已完成
1 期
An Open Label Study to Describe the Pharmacokinetics of Cefazolin in Preterm NeonatesSepsisPrematurityNCT00850122Phillip Brian Smith9
已完成
1 期
Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Seladelpar in Subjects With Hepatic Impairment and Healthy SubjectsHepatic ImpairmentNCT03369002CymaBay Therapeutics, Inc.32
Unknown
1 期
A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic MalignanciesLocally Advanced Solid TumorMetastatic Solid TumorHematologic MalignanciesNCT05028478Curon Biopharmaceutical (Australia) Co Pty Ltd164